A method for detecting a melanoma in a subject in need thereof, comprising: determining the expression level of at least 29 RNA biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 29 RNA biomarkers, wherein the at least 29 RNA biomarkers comprise ATL1, ATP6V0D, C1ORF21, CFLAR, CFLAR-AS1, CHP1, DDX55, DMD, DNAJC9, ENOSF1, FANCL, HJURP, HLA-DOA, HLA-DRA, HNRNPA3P1, IL23A, IQGAP1, LOC494127, LOC646471, LOH12CR, PBXIP1, RNF5, SERTAD2, SLC35G5, SPATS2L, TDRD7, TXK, YY2, and at least one housekeeping gene; normalizing the expression level of each of ATL1, ATP6V0D, C1ORF21, CFLAR, CFLAR-AS1, CHP1, DDX55, DMD, DNAJC9, ENOSF1, FANCL, HJURP, HLA-DOA, HLA-DRA, HNRNPA3P1, IL23A, IQGAP1, LOC494127, LOC646471, LOH12CR, PBXIP1, RNF5, SERTAD2, SLC35G5, SPATS2L, TDRD7, TXK, and YY2 to the expression level of the at least one housekeeping gene, thereby obtaining a normalized expression level of each of ATL1, ATP6V0D, C1ORF21, CFLAR, CFLAR-AS1, CHP1, DDX55, DMD, DNAJC9, ENOSF1, FANCL, HJURP, HLA-DOA, HLA-DRA, HNRNPA3P1, IL23A, IQGAP1, LOC494127, LOC646471, LOH12CR, PBXIP1, RNF5, SERTAD2, SLC35G5, SPATS2L, TDRD7, TXK, and YY2; inputting each normalized expression level into an algorithm to generate a score; comparing the score with a predetermined cutoff value; and identifying the presence of a melanoma in the subject when the score is equal to or greater than the predetermined cutoff value or identifying the absence of a melanoma in the subject when the score is below the predetermined cutoff value, wherein the predetermined cutoff value is 20 on a scale of 0 to 100. determining the expression level of at least 29 RNA biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 29 RNA biomarkers, wherein the at least 29 RNA biomarkers comprise ATL1, ATP6V0D, C1ORF21, CFLAR, CFLAR-AS1, CHP1, DDX55, DMD, DNAJC9, ENOSF1, FANCL, HJURP, HLA-DOA, HLA-DRA, HNRNPA3P1, IL23A, IQGAP1, LOC494127, LOC646471, LOH12CR, PBXIP1, RNF5, SERTAD2, SLC35G5, SPATS2L, TDRD7, TXK, YY2, and at least one housekeeping gene; normalizing the expression level of each of ATL1, ATP6V0D, C1ORF21, CFLAR, CFLAR-AS1, CHP1, DDX55, DMD, DNAJC9, ENOSF1, FANCL, HJURP, HLA-DOA, HLA-DRA, HNRNPA3P1, IL23A, IQGAP1, LOC494127, LOC646471, LOH12CR, PBXIP1, RNF5, SERTAD2, SLC35G5, SPATS2L, TDRD7, TXK, and YY2 to the expression level of the at least one housekeeping gene, thereby obtaining a normalized expression level of each of ATL1, ATP6V0D, C1ORF21, CFLAR, CFLAR-AS1, CHP1, DDX55, DMD, DNAJC9, ENOSF1, FANCL, HJURP, HLA-DOA, HLA-DRA, HNRNPA3P1, IL23A, IQGAP1, LOC494127, LOC646471, LOH12CR, PBXIP1, RNF5, SERTAD2, SLC35G5, SPATS2L, TDRD7, TXK, and YY2; inputting each normalized expression level into an algorithm to generate a score; comparing the score with a predetermined cutoff value; and identifying the presence of a melanoma in the subject when the score is equal to or greater than the predetermined cutoff value or identifying the absence of a melanoma in the subject when the score is below the predetermined cutoff value, wherein the predetermined cutoff value is 20 on a scale of 0 to 100. <EOS>